Ovid Therapeutics Inc (OVID) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Ovid Therapeutics Inc (OVID) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH2428912D
  • |
  • Pages: 45
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Ovid Therapeutics Inc (Ovid Therapeutics) is a bio-pharmaceutical company which identifies, discovers, and develops medicines for neurological disorders. The company's pipeline products are indicated for diseases such as Angelman Syndrome and Fragile X Syndrome. It develops, assess, commercialize compounds and expand its product pipeline through research and development, acquisitions and combination therapies. Ovid Therapeutics works in partnership with patients, clinicians and scientists, foundations, academic centers, regulatory agencies, and companies that help the development of novel therapies. The company has collaboration with Lundbeck and Angelman Syndrome foundations. Ovid Therapeutics is headquartered in New York, the US.

Ovid Therapeutics Inc (OVID)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Ovid Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Ovid Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9

Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Ovid Therapeutics Raises USD25.8 Million in Venture Financing 11

Partnerships 12

Ovid Therapeutics and NeuroPointDX Enter into Agreement 12

Takeda Pharma and Ovid Therapeutics Enter into Agreement 13

Licensing Agreements 15

Ovid Therapeutics Enters into Licensing Agreement with Northwestern University 15

Lundbeck Enters into Licensing Agreement with Ovid Therapeutics for Gaboxadol 17

Equity Offering 18

Ovid Therapeutics Plans to Raise up to USD200 Million in Public Offering of Securities 18

Ovid Therapeutics Raises USD75 Million in IPO 19

Ovid Therapeutics Raises Funds through Private Placement 21

Ovid Therapeutics Raises USD1 Million in Second Tranche of Private Placement of Shares 23

Ovid Therapeutics Raises USD4 Million in First Tranche of Private Placement of Shares 24

Ovid Therapeutics Inc-Key Competitors 25

Ovid Therapeutics Inc-Key Employees 26

Ovid Therapeutics Inc-Locations And Subsidiaries 27

Head Office 27

Other Locations & Subsidiaries 27

Recent Developments 28

Financial Announcements 28

Aug 09, 2018: Ovid Therapeutics reports second quarter 2018 financial results and highlights recent clinical progress 28

May 08, 2018: Ovid Therapeutics Reports First Quarter 2018 Financial Results and Corporate Progress 31

Mar 29, 2018: Ovid Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Corporate Progress 34

Nov 09, 2017: Ovid Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Progress 36

Aug 10, 2017: Ovid Therapeutics Reports Second Quarter 2017 Financial Results and Corporate Progress 38

Jun 13, 2017: Ovid Therapeutics Reports First Quarter 2017 Financial Results and Recent Corporate Progress 40

Corporate Communications 42

Sep 04, 2018: Dr. Yaron Werber, Chief Business and Financial Officer of Ovid Therapeutics, to Return to Wall Street 42

Jun 23, 2017: Ovid Therapeutics to be Added to Russell 2000, 3000 and Microcap Indexes 43

Jun 14, 2017: Ovid Therapeutics Appoints Barbara G. Duncan to its Board of Directors 44

Appendix 45

Methodology 45

About GlobalData 45

Contact Us 45

Disclaimer 45

List of Figures

Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Ovid Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9

List of Tables

Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Ovid Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Ovid Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Ovid Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9

Ovid Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Ovid Therapeutics Raises USD25.8 Million in Venture Financing 11

Ovid Therapeutics and NeuroPointDX Enter into Agreement 12

Takeda Pharma and Ovid Therapeutics Enter into Agreement 13

Ovid Therapeutics Enters into Licensing Agreement with Northwestern University 15

Lundbeck Enters into Licensing Agreement with Ovid Therapeutics for Gaboxadol 17

Ovid Therapeutics Plans to Raise up to USD200 Million in Public Offering of Securities 18

Ovid Therapeutics Raises USD75 Million in IPO 19

Ovid Therapeutics Raises Funds through Private Placement 21

Ovid Therapeutics Raises USD1 Million in Second Tranche of Private Placement of Shares 23

Ovid Therapeutics Raises USD4 Million in First Tranche of Private Placement of Shares 24

Ovid Therapeutics Inc, Key Competitors 25

Ovid Therapeutics Inc, Key Employees 26

Ovid Therapeutics Inc, Other Locations 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Ovid Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17500
Site License
USD 500 INR 35000
Corporate User License
USD 750 INR 52500

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com